Barclays Maintains Underweight on Zimmer Biomet Holdings, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Underweight rating on Zimmer Biomet Holdings (NYSE:ZBH) and raises the price target from $116 to $120.

August 04, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays maintains an Underweight rating on Zimmer Biomet Holdings but raises the price target from $116 to $120.
While the Underweight rating suggests that Barclays expects Zimmer Biomet's stock to underperform, the raised price target indicates a slightly more positive outlook. However, the impact on the stock price in the short term is uncertain as the two signals are somewhat contradictory.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100